Bayer AG Stock
€38.95
Your prediction
Bayer AG Stock
Bayer is a multinational pharmaceutical and life sciences company headquartered in Germany. The company was founded in 1863 and has since grown to become a global leader in the fields of pharmaceuticals, agriculture, and consumer health. Bayer is listed on the Frankfurt Stock Exchange and also trades over-the-counter in the United States under the ticker symbol BAYZF. The company's products include prescription drugs, over-the-counter medicines, and agrochemicals, and it operates in more than 90 countries around the world.
Pros and Cons of Bayer AG in the next few years
Pros
Cons
Performance of Bayer AG vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Bayer AG | -1.520% | 2.433% | 7.345% | 96.123% | 5.299% | -24.749% | -24.865% |
| Merck KGaA | 0.780% | 5.694% | 9.368% | -9.219% | 5.478% | -32.900% | -9.979% |
| Biogen Inc. | 1.030% | 6.258% | 6.574% | 10.821% | 7.641% | -36.992% | -21.870% |
| Johnson & Johnson | -0.590% | -0.746% | 2.116% | 27.161% | -0.611% | 7.359% | 34.174% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Bayer, with its US ticker symbol BAYZF, is a prominent player in the pharmaceuticals industry, boasting a rich history and a diverse portfolio. A deep dive into Bayer's financials reveals a complex picture—while there are some strengths and opportunities for growth, several areas raise concerns.
When analyzing Bayer's financials, several key aspects come into play, revealing both positives and negatives that deserve attention. The company's total assets stood at approximately €123.34 billion in 2023, slightly up from €124.88 billion in 2022. A noticeable highlight is Bayer’s gross profit, which peaked at around €27.8 billion in 2023, reflecting robust revenue generation capabilities even amidst some operational challenges.
*Pros: *
Comments
News
Bayer and Soufflé Therapeutics Announce Strategic Collaboration to Advance Cell-Specific Heart-Targeted siRNA Therapy
Bayer and Soufflé Therapeutics™, an innovative biotech company that discovers and develops cell-selective genetic therapies, today announced a strategic collaboration and global licensing agreement
Bayer to Present Updates on Pharma Growth Strategy and Pipeline Advancements at J.P. Morgan’s 44th Annual Healthcare Conference
Bayer will participate in the 44th J.P. Morgan Healthcare Conference 2026 taking place from January 12–15, 2026 in San Francisco. Stefan Oelrich, Member of the Board of Management, Bayer AG, and
Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome
Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is